Hualan Vac(SZ:301207) Ge Long Hui A P P·2026-01-21 10:13Core Viewpoint - The company, Hualan Vaccine, has received approval from the National Medical Products Administration for its recombinant herpes zoster vaccine, indicating a significant step in addressing the growing demand for shingles vaccination in China [1][2]. Group 1: Company Developments - Hualan Vaccine has been granted a clinical trial approval for its recombinant herpes zoster vaccine (CHO cells), which aims to reduce the incidence of shingles and its related complications [1]. - The vaccine is developed using CHO cells, a mature and safe biopharmaceutical platform, ensuring stable and reliable vaccine production [2]. - This product represents an important strategic move for the company in the field of shingles prevention, potentially offering new options for susceptible populations [2]. Group 2: Industry Context - The prevalence of herpes zoster in China is approximately 6.15%, with rates significantly increasing with age, reaching 12.95% in individuals aged 70 and above [1]. - There are currently two marketed shingles vaccines in China, indicating a competitive landscape, but the demand for shingles vaccination is expected to grow due to the aging population and increased public health awareness [2]. - The existing research supports that vaccination can significantly lower the risk of shingles and its complications, highlighting the importance of vaccine development in this area [1].